Organization
Eli Lilly and Company, Indianapolis, United States of America
4 abstracts
Abstract
ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CAREOrg: University Hospital of Bern, Bern, Switzerland, UCL-Saint Luc, Bruxelles, Belgium, University Hospital of Geneva, Geneva, Switzerland, Eli Lilly and Company, Indianapolis, United States of America, Botnar Research Centre, Univ of Oxford, Headington, United Kingdom,
Abstract
BARICITINIB IMPROVES JOINT MOBILITY AFTER INJURY IN A RODENT FORCED-AMBULATION MODELOrg: Eli Lilly and Company, Indianapolis, United States of America,
Abstract
BENEFITS OF PAIN RELIEF ON FATIGUE, FUNCTION, AND QUALITY OF LIFE WHEN JOINT INFLAMMATION IS CONTROLLED IN PATIENTS WITH RAOrg: Eli Lilly and Company, Indianapolis, United States of America, Botnar Research Centre, Univ of Oxford, Headington, Oxford, United Kingdom,
Abstract
BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSIONOrg: Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, Univ of Occupational and Environmental Health, Kitakyushu, Japan, Johns Hopkins Univ School of Medicine, Baltimore, United States of America, Medical Univ of Vienna, Vienna, Austria, Eli Lilly and Company, Indianapolis, United States of America,